Cover Image

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time....

Full description

Saved in:
Bibliographic Details
Main Authors: Hughes, Timothy P. (Author) , Hochhaus, Andreas (Author) , Branford, Susan (Author) , Müller, Martin Christian (Author) , Kaeda, Jaspal S. (Author) , Foroni, Letizia (Author) , Druker, Brian J. (Author) , Guilhot, François (Author) , Larson, Richard A. (Author) , O'Brien, Stephen G. (Author) , Rudoltz, Marc S. (Author) , Mone, Manisha (Author) , Wehrle, Elisabeth (Author) , Modur, Vijay (Author) , Goldman, John M. (Author) , Radich, Jerald P. (Author)
Format: Article (Journal)
Language:English
Published: November 11, 2010
In: Blood
Year: 2010, Volume: 116, Issue: 19, Pages: 3758-3765
ISSN:1528-0020
DOI:10.1182/blood-2010-03-273979
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2010-03-273979
Get full text
Author Notes:Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators
Description
Summary:This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343.
Item Description:Gesehen am 01.06.2023
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2010-03-273979

Similar Items